Specifying GMP Drug Substance Manufacturing for a Recombinant Glycosylated Serine Protease Biologic Supporting a Phase 1 Study: A Request-for-Proposal Framework
An early-phase clinical program for a biologic can be no better than the drug substance that supplies it. This article builds a request for proposal (RFP) for a contract manufacturing organization (CMO) to develop and execute a GMP drug substance campaign for a hypothetical recombinant, glycosylated serine protease intended for a first-in-human dose-escalation study in a severe acute inflammatory disease with a risk of multiple organ dysfunction. The class-level rationale is that an enzyme acting in the coagulation and inflammatory pathways has a narrow therapeutic window in which bleeding risk makes consistent potency, purity, and control of product variants the central manufacturing concerns. The RFP specifies a mammalian expression system, three GMP batches, release specifications with potency by two orthogonal activity assays, stability initiated at manufacture, an IND chemistry, manufacturing, and controls (CMC) section, a 15-month schedule, an indicative budget of USD 4.5 to 7.5 million, and weighted selection criteria. Recommendations address confidentiality and intellectual property.Keywords: request for proposal; recombinant glycoprotein; GMP drug substance; Phase 1; CMC; potency assay; ICH Q5A(R2); ICH Q6B
Authors
- Peivand Pirouzi
- Patricia Angelique Mallari
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24425459
- Primary Topic
- Protein purification and stability
- Type
- article
- Field-Weighted Citation Impact
- 0.00